Your session is about to expire
← Back to Search
Virus Therapy
PCUR-101 + ADT for Prostate Cancer
Phase 1
Waitlist Available
Research Sponsored by Pellficure Pharmaceuticals, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, average of 12 months
Awards & highlights
No Placebo-Only Group
Approved for 30 Other Conditions
All Individual Drugs Already Approved
Summary
This trial tests a new drug, PCUR-101, in patients with advanced prostate cancer that doesn't respond to standard treatments. The study aims to find the safest and most effective dose. Once the best dose is identified, more patients will be treated to confirm its safety and effectiveness.
Eligible Conditions
- Prostate Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, average of 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, average of 12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Occurrence of Dose Limiting Toxicity
Secondary study objectives
Determination of pharmacokinetic parameters - Cmax
Determination of pharmacokinetic parameters - T1/2
Determination of pharmacokinetic parameters - Tmax
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Approved for 30 Other Conditions
This treatment demonstrated efficacy for 30 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Trial Design
4Treatment groups
Experimental Treatment
Group I: PCUR-101 Dose Expansion Cohort 3Experimental Treatment2 Interventions
PCUR-101 dosed orally once per day in combination with abiraterone (once per day) and prednisone (twice per day) in 28 day cycles
Group II: PCUR-101 Dose Expansion Cohort 2Experimental Treatment2 Interventions
PCUR-101 in combination with dutasteride dosed orally once per day in 28 day cycles
Group III: PCUR-101 Dose Expansion Cohort 1Experimental Treatment1 Intervention
PCUR-101 dosed orally once per day in 28 day cycles
Group IV: PCUR-101 Dose EscalationExperimental Treatment1 Intervention
PCUR-101 dosed orally once per day in 28 day cycles. Patients will be enrolled into escalating dose levels during the dose escalation phase
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dutasteride
FDA approved
Find a Location
Who is running the clinical trial?
Pellficure Pharmaceuticals, IncLead Sponsor
1 Previous Clinical Trials
12 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have moderate to severe nerve damage.You are expected to live for at least 3 more months.You are taking warfarin along with the study treatment.You have a history of seizures.You are currently taking opioid pain medication for either prostate cancer pain or non-cancer related pain.You cannot be receiving any other experimental drugs or cancer treatments, except for standard hormone therapy, within 4 weeks.You have taken PCUR-101 before.
Research Study Groups:
This trial has the following groups:- Group 1: PCUR-101 Dose Expansion Cohort 3
- Group 2: PCUR-101 Dose Escalation
- Group 3: PCUR-101 Dose Expansion Cohort 1
- Group 4: PCUR-101 Dose Expansion Cohort 2
Awards:
This trial has 3 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 30 Other Conditions - This treatment demonstrated efficacy for 30 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.